Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis

Rhea-AI Summary

Waters (NYSE:WAT) launched BioResolve Peptide and GTxResolve Lipid Phenyl-Hexyl+ and C18+ reversed-phase columns to improve characterization of GLP-1 peptides, insulin, and lipid nanoparticles (LNPs). The platform delivers up to 3x faster GLP-1 analysis and 2x faster LNP component analysis with increased resolving power and sensitivity.

According to Waters, the new columns offer up to 2x higher resolution, QC batch-tested GLP‑1 and LNP methods, improved impurity detection, and compatibility across U(H)PLC and HPLC systems. Global availability begins June 9, 2026, starting with the 1.6 µm Phenyl-Hexyl+ phase.

AI-generated analysis. Not financial advice.

News Market Reaction – WAT

-0.02%

1 alert

-0.02% News Effect

On the day this news was published, WAT declined 0.02%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

GLP-1 speed gain: up to 3x faster LNP analysis speed: 2x faster Resolution and sensitivity: up to 2x increase +5 more

8 metrics

GLP-1 speed gain up to 3x faster GLP-1 characterization versus traditional approaches

LNP analysis speed 2x faster LNP component analysis run times

Resolution and sensitivity up to 2x increase Resolving power and sensitivity for low-level impurities

Pore size 230 Å Particle pore size for Phenyl-Hexyl+ and C18+ chemistries

Column length 300 mm Specialized formats for maximum separation performance

Particle size 1.6 µm Phenyl-Hexyl+ phase initial global availability

Symposium edition 55th International Symposium on High Performance Liquid Phase Separations

Availability date June 9, 2026 Global availability start for new columns

Market Reality Check

Price: $363.18 Vol: Volume 671,180 is below 2...

low vol

$363.18 Last Close

Volume Volume 671,180 is below 20-day average 1,072,013 (relative volume 0.63) ahead of this launch news. low

Technical Trading above 200-day MA, with price at 365.36 versus 200-day MA of 341.97.

Peers on Argus

WAT fell 2.95% while key peers were mixed: DGX up 1.46%, LH up 1.11%, ILMN down ...

WAT fell 2.95% while key peers were mixed: DGX up 1.46%, LH up 1.11%, ILMN down 3.17%, MTD down 2.10%, PKI flat. No clear sector-wide direction or momentum flags.

Historical Context

5 past events · Latest: 2026-06-03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
2026-06-03	Regulatory clearance	Positive	+2.1%	FDA 510(k) clearance for BD BACTEC FXI blood culture system in U.S.
2026-06-01	Product launch	Positive	-1.4%	Launch of Cyclic IMS P20 MS structural and spatial omics platform.
2026-06-01	Product launch	Positive	-1.4%	Unveiling Xevo MRT P10 benchtop HRMS with higher sensitivity and speed.
2026-05-18	Conference appearance	Neutral	+1.2%	CEO fireside chat at Jefferies Global Healthcare Conference.
2026-05-05	Earnings results	Positive	+13.5%	Q1 2026 beat guidance and raised full-year organic growth and EPS outlook.

Pattern Detected

Recent product and regulatory news often saw modest moves, with one strong positive reaction to earnings and some divergence on product launches.

Recent Company History

Over the last few months, Waters reported strong Q1 2026 results on May 5 with a 13.54% positive move, highlighting growth from its Biosciences and Diagnostic Solutions acquisition. Subsequent product launches on June 1 around the Cyclic IMS P20 MS and Xevo MRT P10 MS led to small negative reactions of -1.41%. FDA 510(k) clearance news on June 3 produced a modest 2.11% gain, while a Jefferies conference appearance on May 18 coincided with a 1.16% rise. Today’s column launch fits an ongoing innovation cadence.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-03-16

An automatic shelf registration on March 16, 2026 allows Waters and affiliates to offer an indeterminate amount of common stock, preferred stock, debt securities, guarantees, warrants and other instruments from time to time. The filing is effective (Form S-3ASR) and has already been used once via a 424B2 supplement.

Market Pulse Summary

This announcement highlights Waters’ focus on biopharma workflows, introducing reversed-phase column...

Analysis

This announcement highlights Waters’ focus on biopharma workflows, introducing reversed-phase columns aimed at GLP‑1 and LNP impurity analysis with up to 3x faster characterization and 2x faster component analysis. The launch follows a series of recent MS platform introductions and strong Q1 2026 growth. Investors may watch how quickly these consumables gain adoption, how they support regulatory readiness for complex biologics, and how they complement the larger post-acquisition product portfolio.

Key Terms

reversed-phase, glp-1, lipid nanoparticles, hplc, +2 more

6 terms

reversed-phase technical

"a first-of-its-kind reversed-phase (RP) column platform designed to tackle"

Reversed-phase chromatography is a lab technique that separates molecules based on whether they prefer oil-like or water-like environments; a non‑polar surface holds onto fat‑loving compounds while a water‑based liquid carries off the more polar ones. Investors care because this method is widely used for purity testing, measuring active ingredients and stability checks—essential quality and regulatory evidence that can affect product approvals, production reliability and financial risk.

glp-1 medical

"3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

lipid nanoparticles medical

"similar impurities in GLP-1 peptides, insulin, and lipid nanoparticles (LNPs)"

Lipid nanoparticles are tiny, fat-like capsules that carry and protect drug molecules or genetic material until they reach target cells, where they help the payload enter and work. Think of them as microscopic delivery trucks or soap bubbles that keep fragile cargo safe and steer it to the right address. Investors care because this delivery technology can make medicines more effective, shape manufacturing costs and capacity, create patent and regulatory value, and influence commercial potential for therapies.

hplc technical

"consistent performance across U(H)PLC and HPLC systems, and reliable"

High-performance liquid chromatography (HPLC) is a lab method that separates, identifies and measures the individual chemicals in a liquid sample, like sorting mixed beads by size as they pass through a narrow tube. Investors care because HPLC is a routine tool for quality control, purity testing and regulatory compliance in drug, food and chemical manufacturing, so its results affect product approvals, batch releases, production costs and company credibility.

mass spectrometry technical

"speed with a mass spectrometry-based QC approach, we can now satisfy"

Mass spectrometry is a laboratory technique that identifies and measures chemicals by giving molecules an electrical charge and sorting them by how fast they move, like weighing and separating coins to see which kinds are present. For investors, its results are evidence used in drug development, quality control, food and environmental testing, and diagnostics, so clear mass-spec data can affect regulatory approval, product reliability, costs and market confidence.

ionizable lipids medical

"charged surface of GTxResolve Columns helps sharpen peaks for ionizable lipids"

Ionizable lipids are fat-like molecules used to package and deliver fragile medicines such as RNA inside tiny particles; they change their electrical charge depending on the surrounding acidity to hold cargo during manufacturing and release it inside cells. Investors care because these molecules are central to the effectiveness, safety, and manufacturability of many novel therapeutics and vaccines—think of them as the delivery box and timed-release latch that determine whether a drug performs reliably at scale.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks.
• Delivers up to 2x increase in resolving power and sensitivity to identify and track low-level impurities for improved regulatory readiness.
• Industry-first chemical and physical particle optimization delivers reproducible methods for increasingly complex biologics.

MILFORD, Mass., June 8, 2026 /PRNewswire/ -- 55th International Symposium on High Performance Liquid Phase Separations and Related Techniques—Waters Corporation (NYSE: WAT) today announced the launch of the BioResolve™ Peptide and GTxResolve™ Lipid Phenyl-Hexyl+ and C18+ Columns, a first-of-its-kind reversed-phase (RP) column platform designed to tackle a persistent biopharmaceutical challenge: reliably separating structurally and chemically similar impurities in GLP-1 peptides, insulin, and lipid nanoparticles (LNPs) to support the development of safe, effective drug products.

In GLP-1 receptor agonists and newer mRNA-based therapies such as in vivo CAR T, difficulty resolving impurities can delay time to market, weaken regulatory confidence, and affect patient safety. Traditional RP columns do not always separate low-level or closely related impurities well, often requiring longer analyses, detector-suppressing mobile-phase additives, or repeated method redevelopment. BioResolve Peptide and GTxResolve Lipid Columns help to overcome these limitations with ready-to-use methods that improve both resolution^1,2 and speed^2,3 while fitting into existing workflows.

"We have made simultaneous advances in both chemistry and particle physics to deliver the first columns Waters has introduced to market specifically QC batch-tested for GLP‑1 analysis⁴ and lipid nanoparticles,² solving a longstanding customer pain point," said Erin Chambers, Vice President, General Manager, Consumables & Lab Automation, Waters Analytical Sciences, Waters Corporation. "BioResolve Peptide and GTxResolve Lipid Columns are designed to resolve chemically similar GLP‑1 impurities and LNP components faster when speed matters,^2,3 and with extraordinary resolution¹ when certainty is required. The result is simpler method development, regulatory‑ready data,⁵ and faster, highly reproducible methods, ultimately helping to reduce cost burdens on important new therapeutics."

BioResolve Peptide and GTxResolve Lipid Columns use specially designed surface chemistries and superficially porous particles to deliver precise RP separations with selectivity for two difficult sample types. Available in Phenyl-Hexyl+ and C18+ chemistries with 230 Å pore size particles, they are designed to support efficient mass transfer, consistent performance across U(H)PLC and HPLC systems, and reliable, batch-tested results⁵ from early-stage research through manufacturing.

GLP-1 peptides are especially challenging to analyze because many impurities differ by just one atom, while others have no difference in atomic composition and vary only in how their atoms are arranged spatially. BioResolve Peptide Phenyl-Hexyl+ and C18+ Columns are built to resolve these difficult impurities, with specialized 300 mm formats available when maximum separation performance and deeper impurity characterization are required.

"The BioResolve Peptide RP Columns have performed exceptionally well, showing outstanding resolution between our peptide therapeutics and related impurities," said Ashish Kanhed, Group Leader, Alembic Pharmaceuticals. "We are highly impressed with their quality and look forward to continuing to use them for our complex GLP-1 and peptide separations. By discriminating critical impurities at speed with a mass spectrometry-based QC approach, we can now satisfy present and future regulatory requirements in one run for faster, more confident answers on molecular purity."

For LNP and lipid workflows, the charged surface of GTxResolve Columns helps sharpen peaks for ionizable lipids by reducing tailing. Their larger pore size makes it easier for a wide range of lipid molecules to move through the column, improving peak shape and resolving challenging co-elutions. In addition, the superficially porous particle design speeds the movement of molecules through the stationary phase, shortening run times without reducing selectivity.²

"GTxResolve Lipid RP Columns have demonstrated strong performance for lipid quantitation and impurity analysis, with reduced run times and excellent peak shape," said Adam Kowalczyk, Research Scientist II, Analytical Development, Acuitas Therapeutics. "The ability to tune separations for specific lipid components, combined with compatibility across multiple detector platforms (UV, MS, ELSD, and CAD), provides significant flexibility for characterization of diverse lipid species. In particular, we have observed a separation of ionizable lipids that has not previously been achieved."

Waters' BioResolve Peptide and GTxResolve Lipid Columns will be available globally beginning June 9, 2026, starting with the 1.6 µm Phenyl-Hexyl+ phase.  For more information, please visit waters.com/BioResolve and waters.com/GTx.

Additional Resources:

• BioResolve Peptide Columns product page
• GTxResolve Lipid Columns product page

Waters, BioResolve, GTxResolve, and Empower are trademarks of Waters Corporation or its affiliates. All other trademarks are the property of their respective owners.

About Waters Corporation:

Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and services. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of approximately 16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. For more information, please visit www.waters.com/about. 

References:

1. As demonstrated on Waters Literature Code: 720009327EN "Supercharged Peptide Chromatography" when compared to a competitor superficially porous particle technology.
2. As demonstrated on Waters Literature Code: 720009330EN "Lipid Nanoparticle Total Solution Analysis" when compared to fully porous particle technology.
3. As demonstrated on Waters Literature Code: 720009327EN "Supercharged Peptide Chromatography" when compared to fully porous particle technology.
4. QC batch testing approaches based on insulin, semaglutide, tirzepatide, cagrilintide, and liraglutide are highlighted in Waters Literature Code: 720009327EN "Supercharged Peptide Chromatography."
5. Application note: "Automating Charged Aerosol Detection (CAD) Analysis with Empower™ CDS Using a Single-Vendor Integrated LC Platform."

Contact:   

Molly Gluck  
Head of External Communications
Waters Corporation  
508.498.9732
molly_gluck@waters.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/waters-launches-industry-first-reversed-phase-bioseparation-columns-to-deliver-up-to-3x-faster-glp-1-characterization-and-2x-faster-lnp-component-analysis-302793672.html

SOURCE Waters Corporation

FAQ

What did Waters (NYSE:WAT) announce on June 8, 2026 about GLP-1 and LNP analysis?

Waters announced BioResolve Peptide and GTxResolve Lipid reversed-phase columns for GLP-1, insulin, and LNP analysis. According to Waters, the platform targets difficult impurity separations, offering higher resolution, faster run times, and ready-to-use methods that fit into existing U(H)PLC and HPLC workflows from research through manufacturing.

How much faster are GLP-1 characterization and LNP component analysis with Waters’ new columns?

The new columns enable up to 3x faster GLP-1 characterization and 2x faster LNP component analysis. According to Waters, superficially porous particles and tailored surface chemistries shorten run times while maintaining selectivity, helping labs reduce bottlenecks in biopharmaceutical development and quality control testing.

How do Waters BioResolve Peptide Columns improve GLP-1 and insulin impurity resolution for WAT investors to consider?

BioResolve Peptide Columns are designed to resolve GLP-1 and insulin impurities differing by as little as one atom. According to Waters, specialized Phenyl-Hexyl+ and C18+ chemistries, plus 300 mm formats, enhance separation performance and deeper impurity characterization for regulatory-ready data and reproducible QC methods.

What advantages do GTxResolve Lipid Columns offer for LNP component analysis in mRNA and gene therapies?

GTxResolve Lipid Columns use a charged surface to sharpen peaks for ionizable lipids and reduce tailing. According to Waters, larger pore sizes and superficially porous particles improve peak shape, resolve challenging co-elutions, and cut run times while remaining compatible with UV, MS, ELSD, and CAD detectors.

When will Waters’ BioResolve Peptide and GTxResolve Lipid Columns be available globally?

Waters plans global availability of the BioResolve Peptide and GTxResolve Lipid Columns starting June 9, 2026. According to Waters, the rollout begins with the 1.6 µm Phenyl-Hexyl+ phase, supporting applications from early-stage research to manufacturing for GLP-1 peptides and lipid nanoparticles.

Are Waters’ new reversed-phase columns compatible with existing UPLC and HPLC systems?

Yes, the columns are designed for consistent performance across U(H)PLC and HPLC systems. According to Waters, superficially porous particles, 230 Å pore sizes, and QC batch-tested methods help deliver reliable results that can be integrated into current biopharmaceutical workflows without major system changes.

How do Waters’ new columns support regulatory readiness for GLP-1 and LNP-based drugs?

The columns support regulatory readiness by improving detection of low-level and closely related impurities in GLP-1 and LNP samples. According to Waters, higher sensitivity, up to 2x resolving power, and mass spectrometry-based QC methods help generate regulatory-ready impurity profiles in a single run.